학술논문

Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA
Document Type
Article
Source
In: Proteomics - Clinical Applications. (Proteomics - Clinical Applications, March 2022, 16(2))
Subject
Language
English
ISSN
18628354
18628346